AstraZeneca PLC Share Price

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 09:05:06 21/06/2024 pm IST 5-day change 1st Jan Change
12,472 GBX +0.60% Intraday chart for AstraZeneca PLC -0.30% +17.66%
Sales 2024 * 51.66B 4,315B Sales 2025 * 55.54B 4,640B Capitalization 244B 20,393B
Net income 2024 * 8.76B 732B Net income 2025 * 10.42B 871B EV / Sales 2024 * 5.13 x
Net Debt 2024 * 20.76B 1,734B Net Debt 2025 * 14.18B 1,184B EV / Sales 2025 * 4.65 x
P/E ratio 2024 *
27.8 x
P/E ratio 2025 *
23.4 x
Employees 89,900
Yield 2024 *
1.95%
Yield 2025 *
2.06%
Free-Float 96.64%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AstraZeneca PLC

1 day+0.60%
1 week-0.30%
Current month+2.31%
1 month+0.91%
3 months+18.98%
6 months+19.51%
Current year+17.66%
More quotes
1 week
12 164.00
Extreme 12164
12 562.00
1 month
11 858.00
Extreme 11858
12 704.00
Current year
9 461.00
Extreme 9461
12 704.00
1 year
9 461.00
Extreme 9461
12 704.00
3 years
8 029.00
Extreme 8029
12 704.00
5 years
5 871.00
Extreme 5871
12 704.00
10 years
3 680.00
Extreme 3680
12 704.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 01/12/01
Director of Finance/CFO 50 01/21/01
Chief Tech/Sci/R&D Officer - 01/23/01
Members of the board TitleAgeSince
Director/Board Member 65 01/17/01
Director/Board Member 63 27/17/27
Director/Board Member 68 01/99/01
More insiders
Date Price Change Volume
21/24/21 12,472 +0.60% 6,183,289
20/24/20 12,398 +0.47% 1,559,325
19/24/19 12,340 -0.61% 943,032
18/24/18 12,416 -0.10% 1,604,675
17/24/17 12,428 -0.66% 1,122,268

Delayed Quote London S.E., June 21, 2024 at 09:05 pm IST

More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.5 USD
Average target price
174.4 USD
Spread / Average Target
+10.77%
Consensus